Swedish NeoDynamic has issued shares with a value of 22.5 MSEK to Boai NKY Pharmaceuticals Ltd, a publicly traded company based in Jiaozuo, China.
NeoDynamics welcomes a strong owner with good contacts into the Chinese market.
The company has developed a new technology and needle design supporting the development within the breast cancer field and doctors’ need for new precision instruments for tissue sampling. The company achieved CE approval for its device NeoNavia in July.
“Creating a simplified treatment process for breast cancer patients could lead to both cost savings and a better experience for the patient,” says Anna Eriksrud of NeoDynamics.
“The company is now ready to enter its biopsy technology to the market after several years of development. We have developed a good product and we also have a strong partner, Boai, which also can contribute with important contacts on the Chinese market,” says Jörgen Vrenning, CFO of the company.